Opendata, web and dolomites

DIALYBRID

Revolutionising the world of hemodialysis with a novel, hybrid, silk fibroin/polyurethane vascular access

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 DIALYBRID project word cloud

Explore the words cloud of the DIALYBRID project. It provides you a very rough idea of what is the project "DIALYBRID" about.

polyurethane    saving    alternatives    msca    urgent    ip    de    risk    reg    semidegradable    worldwide    scenario    business    action    vascular    blend    trademarked    enter    certification    therapy    market    frequency    skilled    interventions    global    sustaining    patency    infective    silk    ftes    society    industrialization    manufactured    silkothane    clinical    validation    materials    diabetes    plan    life    longer    trl    verify    innovative    technological    hypertension    diversify    remodeling    million    cannulation    accesses    hybrid    placement    re    sme    sag    delivering    live    granting    venture    2030    consequence    nanostructured    bel    health    arteriovenous    28    fact    costly    electrospinning    people    master    competitiveness    patients    portfolio       2025    reached    fibroin    38    limitations    create    hemodialysis    proposes    revolutionize    viability    renal    graft    soundness    commercialization    jobs    36    opportunity    reducing    quality    54m    members    meet    470    functioning    integration    bottleneck    human    increment    complications    auspices    frequent    view    suffer    productivity    turnover    commercial   

Project "DIALYBRID" data sheet

The following table provides information about the project.

Coordinator
BIOENGINEERING LABORATORIES 

Organization address
address: VIA VIVALDI 32/A
city: CANTU'
postcode: 22063
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.bioengineeringlab.com/eng/sme-instrument-phase-1-dialybrid-december-1-2018/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIOENGINEERING LABORATORIES IT (CANTU') coordinator 50˙000.00

Map

 Project objective

Vascular access is the bottleneck to long-term hemodialysis for about 2.2 million people worldwide who need this life-saving/life-sustaining therapy in case of renal failure, e.g. as a consequence of diabetes and/or hypertension. The current alternatives of vascular access suffer in fact from several limitations, e.g. the need for frequent and costly re-interventions, reduced patency, infective complications. To meet this urgent, global, clinical need, BEL proposes SAG (Silkothane® Arteriovenous Graft), an innovative, hybrid, semidegradable, nanostructured vascular access, manufactured by electrospinning using Silkothane®, a silk fibroin/polyurethane blend developed and trademarked by BEL under the auspices of a MSCA action. Enabling early cannulation and easy placement, as well as remodeling, patency, and integration on the long term, SAG will revolutionize the scenario of hemodialysis vascular accesses worldwide by: reducing the frequency of complications and re-interventions (thus health costs); granting broader access to hemodialysis; improving the patients’ quality of life, enabling them to live longer as functioning members of the society. SAG has reached TRL 6. Phase 1 would allow BEL to verify the soundness of SAG’s venture (with a Business Plan and an IP Management Plan), and to de-risk the technological viability of the industrialization (delivering Essential Requirements, Risk Analysis, Validation Master Plan, Industrialization Plan), in view of future clinical studies, certification and commercialization. SAG represents for BEL an important opportunity to diversify its product portfolio, enter the market of Advanced Materials, experience growth in productivity and competitiveness and create new jobs. As the commercial potential of SAG is estimated to be around 28 million € in 2025 and 54M€ in 2030, in 2025 the SME would experience an increment in turnover of about 470%, and a 36% increase (from 28 FTEs to 38 FTEs) in highly skilled human resources.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DIALYBRID" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DIALYBRID" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Savesight (2020)

Contact lens embedded sensor for ocular hypertension and glaucoma monitoring

Read More  

Proteus 25 (2018)

Developing the world’s first food wrapping machine with organic film

Read More  

ALR4000 (2019)

Automated LCD Recycling series 4000

Read More